Innate Pharma prices unregistered private placement of 17,647,059 shares at EUR 1.7 each

• Innate Pharma priced a private placement of 17,647,059 new ordinary shares at EUR 1.7 each, raising gross proceeds of about EUR 30 million.
• Net proceeds expected at EUR 27.6 million, factoring EUR 2.4 million of bookrunner commissions and offering expenses.
• Closing targeted for Aug. 18, 2026, with the new shares set to trade on Euronext Paris on the same line.
• Proceeds earmarked mainly for IPH4502 clinical development, progression of preclinical ADC candidates, working capital, general corporate purposes.
• Issuance expected to dilute existing shareholders by about 18.76% on a non-diluted basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.